Future direction The evolution of GLP-1RAs is increasingly shifting toward oral formulations, aiming to enhance patient adherence by eliminating the need for injections and addressing the logistical complexities associated with traditional peptide therapies [72, 73]
The FDA allowed this under a shortage exception clause in Section 503A of the FDCA, which permits compounding if the branded drug is on the FDAs shortage list
Its based on five key microbial markers: Akkermansia , Butyrate, Faecalibacterium , Acetate, and Propionate
Vaccaro, C., Zhou, J., Ober, R
KM: Many people are caught between a rock and a hard place financially, and there are some hard choices we have to make about these medications
Trial participation is separate from ordering a research peptide